Australia markets close in 3 hours 33 minutes

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
63.63-2.13 (-3.24%)
As of 10:24AM CST. Market open.
Currency in CNY

Valuation measures4

Market cap (intra-day) 8.85B
Enterprise value 8.01B
Trailing P/E 15.88
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.46
Price/book (mrq)2.46
Enterprise value/revenue 4.97
Enterprise value/EBITDA 12.62

Trading information

Stock price history

Beta (5Y monthly) 2.49
52-week change 3-21.26%
S&P500 52-week change 326.43%
52-week high 386.13
52-week low 344.78
50-day moving average 360.85
200-day moving average 364.84

Share statistics

Avg vol (3-month) 32.01M
Avg vol (10-day) 32.58M
Shares outstanding 5134.65M
Implied shares outstanding 6134.65M
Float 869.75M
% held by insiders 136.54%
% held by institutions 119.65%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 42
Forward annual dividend yield 43.04%
Trailing annual dividend rate 32.00
Trailing annual dividend yield 33.04%
5-year average dividend yield 4N/A
Payout ratio 412.07%
Dividend date 3N/A
Ex-dividend date 408 May 2024
Last split factor 21.5:1
Last split date 325 May 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 34.37%
Operating margin (ttm)54.20%

Management effectiveness

Return on assets (ttm)10.47%
Return on equity (ttm)16.32%

Income statement

Revenue (ttm)1.61B
Revenue per share (ttm)12.05
Quarterly revenue growth (yoy)12.00%
Gross profit (ttm)N/A
EBITDA 718.85M
Net income avi to common (ttm)553.49M
Diluted EPS (ttm)4.14
Quarterly earnings growth (yoy)42.10%

Balance sheet

Total cash (mrq)1.06B
Total cash per share (mrq)7.98
Total debt (mrq)210.19M
Total debt/equity (mrq)5.84%
Current ratio (mrq)4.49
Book value per share (mrq)27.16

Cash flow statement

Operating cash flow (ttm)655.68M
Levered free cash flow (ttm)249.94M